|
1
|
Francis H, Alpini G and DeMorrow S: Recent
advances in the regulation of cholangiocarcinoma growth. Am J
Physiol Gastrointest Liver Physiol. 299:G1–G9. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
de Marsh RW, Alonzo M, Bajaj S, et al:
Comprehensive review of the diagnosis and treatment of biliary
tract cancer 2012. Part I: diagnosis-clinical staging and
pathology. J Surg Oncol. 106:332–338. 2012. View Article : Google Scholar
|
|
3
|
von Hahn T, Ciesek S, Wegener G, et al:
Epidemiological trends in incidence and mortality of hepatobiliary
cancers in Germany. Scand J Gastroenterol. 46:1092–1098. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Marzioni M, Saccomanno S, Candelaresi C,
et al: Clinical implications of novel aspects of biliary
pathophysiology. Dig Liver Dis. 42:238–244. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ciombor KK and Goff LW: Current therapy
and future directions in biliary tract malignancies. Curr Treat
Options Oncol. 14:337–349. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yeung K, Seitz T, Li S, et al: Suppression
of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature.
401:173–177. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yeung KC, Rose DW, Dhillon AS, et al: Raf
kinase inhibitor protein interacts with NF-kappaB-inducing kinase
and TAK1 and inhibits NF-kappaB activation. Mol Cell Biol.
21:7207–7217. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Deiss K, Kisker C, Lohse MJ and Lorenz K:
Raf kinase inhibitor protein (RKIP) dimer formation controls its
target switch from Raf1 to G protein-coupled receptor kinase (GRK)
2. J Biol Chem. 287:23407–23417. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chatterjee D, Bai Y, Wang Z, et al: RKIP
sensitizes prostate and breast cancer cells to drug-induced
apoptosis. J Biol Chem. 279:17515–17523. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Moon A, Park JY, Sung JY, Park YK and Kim
YW: Reduced expression of Raf-1 kinase inhibitory protein in renal
cell carcinoma: a significant prognostic marker. Pathology.
44:534–539. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yun J, Frankenberger CA, Kuo WL, et al:
Signalling pathway for RKIP and Let-7 regulates and predicts
metastatic breast cancer. EMBO J. 30:4500–4514. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Beshir AB, Ren G, Magpusao AN, et al: Raf
kinase inhibitor protein suppresses nuclear factor-κB-dependent
cancer cell invasion through negative regulation of matrix
metalloproteinase expression. Cancer Lett. 299:137–149. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ma J, Li F, Liu L, et al: Raf kinase
inhibitor protein inhibits cell proliferation but promotes cell
migration in rat hepatic stellate cells. Liver Int. 29:567–574.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhao D, Ma J, Shi J, et al: Raf kinase
inhibitor protein inhibits esophageal cancer cell invasion through
downregulation of matrix metalloproteinase expression. Oncol Rep.
30:304–312. 2013.PubMed/NCBI
|
|
15
|
Birner P, Jesch B, Schultheis A and
Schoppmann SF: RAF-kinase inhibitor protein (RKIP) downregulation
in esophageal cancer and its metastases. Clin Exp Metastasis.
29:551–559. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Braconi C and Patel T: Cholangiocarcinoma:
new insights into disease pathogenesis and biology. Infect Dis Clin
North Am. 24:871–884. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nathan H, Aloia TA, Vauthey JN, et al: A
proposed staging system for intrahepatic cholangiocarcinoma. Ann
Surg Oncol. 16:14–22. 2009. View Article : Google Scholar
|
|
18
|
Ribero D, Nuzzo G, Amisano M, et al:
Comparison of the prognostic accuracy of the sixth and seventh
editions of the TNM classification for intrahepatic
cholangiocarcinoma. HPB (Oxford). 13:198–205. 2011.
|
|
19
|
Lorenz K, Lohse MJ and Quitterer U:
Protein kinase C switches the Raf kinase inhibitor from Raf-1 to
GRK-2. Nature. 426:574–579. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Deiss K, Kisker C, Lohse MJ and Lorenz K:
Raf kinase inhibitor protein (RKIP) dimer formation controls its
target switch from Raf1 to G protein-coupled receptor kinase (GRK)
2. J Biol Chem. 287:23407–23417. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Escara-Wilke J, Yeung K and Keller ET: Raf
kinase inhibitor protein (RKIP) in cancer. Cancer Metastasis Rev.
31:615–620. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Maeda T, Kajiyama K, Adachi E, Takenaka K,
Sugimachi K and Tsuneyoshi M: The expression of cytokeratins 7, 19,
and 20 in primary and metastatic carcinomas of the liver. Mod
Pathol. 9:901–909. 1996.PubMed/NCBI
|
|
23
|
Kim HS, Lee SH, Won KY, et al: Expression
of Raf-1 kinase inhibitory protein in carcinoma of the ampulla of
Vater. Virchows Arch. 460:61–68. 2012. View Article : Google Scholar
|
|
24
|
Al-Mulla F, Bitar MS, Taqi Z and Yeung KC:
RKIP: much more than Raf kinase inhibitory protein. J Cell Physiol.
228:1688–1702. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lódi C, Szabó E, Holczbauer A, et al:
Claudin-4 differentiates biliary tract cancers from hepatocellular
carcinomas. Mod Pathol. 19:460–469. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Thummarati P, Wijitburaphat S, Prasopthum
A, et al: High level of urokinase plasminogen activator contributes
to cholangiocarcinoma invasion and metastasis. World J
Gastroenterol. 18:244–250. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Park SY, Kim JH, Won HJ, Shin YM and Kim
PN: Radiofrequency ablation of hepatic metastases after curative
resection of extrahepatic cholangiocarcinoma. AJR Am J Roentgenol.
197:W1129–W1134. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang Q, Tang H, Yin S and Dong C:
Downregulation of microRNA-138 enhances the proliferation,
migration and invasion of cholangiocarcinoma cells through the
upregulation of RhoC/p-ERK/MMP-2/MMP-9. Oncol Rep. 29:2046–2052.
2013.PubMed/NCBI
|
|
29
|
Leelawat K, Sakchinabut S, Narong S and
Wannaprasert J: Detection of serum MMP-7 and MMP-9 in
cholangiocarcinoma patients: evaluation of diagnostic accuracy. BMC
Gastroenterol. 9:302009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
French JJ, Midwinter MJ, Bennett MK, Manas
DM and Charnley RM: A matrix metalloproteinase inhibitor to treat
unresectable cholangiocarcinoma. HPB (Oxford). 7:289–291. 2005.
View Article : Google Scholar
|
|
31
|
Jo Chae K, Rha SY, Oh BK, et al:
Expression of matrix metalloproteinase-2 and -9 and tissue
inhibitor of metalloproteinase-1 and -2 in intraductal and
nonintraductal growth type of cholangiocarcinoma. Am J
Gastroenterol. 99:68–75. 2004. View Article : Google Scholar
|
|
32
|
Selaru FM, Olaru AV, Kan T, et al:
MicroRNA-21 is overexpressed in human cholangiocarcinoma and
regulates programmed cell death 4 and tissue inhibitor of
metalloproteinase 3. Hepatology. 49:1595–1601. 2009. View Article : Google Scholar : PubMed/NCBI
|
